Dear Editor, over the last decades lipid-modifying strategies made a pivotal change
in cardiovascular prevention especially in patients with previous coronary artery
disease or ischemic stroke. In these patients, low-density lipoprotein cholesterol
(LDL-C) reduction is directly correlated to less future cardiovascular events, an
association mediated by its effect on the burden of atherosclerosis [
[1]
]. In contrast to coronary and peripheral artery disease which are mainly caused by
atherosclerosis, stroke is a heterogenous disease with distinct pathophysiological
mechanisms (like atherosclerosis, atrial fibrillation (AF), patent foramen ovale,
dissection, small vessel disease) that frequently overlap [
[2]
]. Of them, about only 10-20% are attributed to atherosclerosis.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The effects of lowering ldl cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials.Lancet. 2012; 380: 581-590
- Prevalence and overlap of potential embolic sources in patients with embolic stroke of undetermined source.Journal of the American Heart Association. 2019; 8e012858
- A comparison of two ldl cholesterol targets after ischemic stroke.New England Journal of Medicine. 2019; 382: 9-19
- Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.Eur. J. Intern. Med. 2016; 34: 54-57
- Effect of alirocumab on stroke in odyssey outcomes.Circulation. 2019; 140: 2054-2062
Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, et al. Stroke prevention with the pcsk9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke.0:STROKEAHA.119.027759.
- Alirocumab and cardiovascular outcomes after acute coronary syndrome.New England Journal of Medicine. 2018; 379: 2097-2107
- Evolocumab and clinical outcomes in patients with cardiovascular disease.New England Journal of Medicine. 2017; 376: 1713-1722
- 2019 esc/eas guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the european society of cardiology (esc) and european atherosclerosis society (eas).European Heart Journal. 2019; 41: 111-188
- Temporal distribution and magnitude of the vulnerability period around stroke depend on stroke subtype.Cerebrovascular Diseases. 2011; 32: 246-253
Article info
Publication history
Published online: January 05, 2021
Accepted:
November 19,
2020
Received in revised form:
September 20,
2020
Received:
September 4,
2020
Identification
Copyright
© 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
